Physician profile
Jaime Roman
NPI 1497092654
$337,515.32
in general payments reported to CMS, 2019-2025
58 companies · $71K in 2025
The $71K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40K · 2022: $86K · 2023: $83K · 2024: $58K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $136K · Travel and Lodging: $58K · Food and Beverage: $13K · Consulting Fee: $2,395 · Honoraria: $1,400 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $750 · Long Term Medical Supply Or Device Loan: $299 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $135,796.65 |
| Travel and Lodging | $57,780.38 |
| Food and Beverage | $12,829.24 |
| Consulting Fee | $2,395.00 |
| Honoraria | $1,400.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $750.00 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $269.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $61,242.51 | 2021-2025 | Calquence, Enhertu, Imfinzi |
| Emd Serono, INC. | $57,901.53 | 2022-2025 | Bavencio, Tepmetko |
| Janssen Biotech, INC. | $45,345.67 | 2021-2025 | Imbruvica, Carvykti, Darzalex |
| Seagen INC. | $39,072.81 | 2021-2023 | Adcetris |
| Pharmaessentia USA Corporation | $29,813.13 | 2022-2025 | Besremi |
| Pharmacyclics LLC, An Abbvie Company | $27,093.87 | 2021-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $26,317.19 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $18,659.67 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $15,534.88 | 2025 | Cosela |
| Pfizer INC. | $4,660.21 | 2022-2025 | |
| G1 Therapeutics, INC. | $4,040.59 | 2022-2023 | Cosela |
| Glaxosmithkline, LLC. | $1,384.45 | 2024-2025 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $1,166.58 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $979.90 | 2022-2025 | |
| Stemline Therapeutics INC. | $893.52 | 2023-2025 | Orserdu |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $363.94 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $319.84 | 2022-2025 | Trodelvy |
| Incyte Corporation | $292.66 | 2022-2025 | Jakafi, Monjuvi |
| Daiichi Sankyo INC. | $251.67 | 2023-2025 | Enhertu, Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $212.98 | 2022-2025 | Opdivo |
| Astellas Pharma US INC | $144.73 | 2023-2025 | Xospata, Vyloy, Padcev |
| Sobi, INC | $137.72 | 2023 | |
| Jazz Pharmaceuticals INC. | $125.79 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $121.02 | 2022-2025 | Libtayo, Lynozyfic |
| Array Biopharma INC | $117.85 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $103.13 | 2022-2024 | Alunbrig, Iclusig, Vonvendi |
| Amgen INC. | $91.79 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Karyopharm Therapeutics INC. | $76.23 | 2022-2025 | Xpovio |
| Lilly USA, LLC | $71.80 | 2023-2025 | Verzenio, Jaypirca |
| Cti Biopharma Corp. | $66.23 | 2023 | Vonjo |
| Morphosys, US INC. | $62.37 | 2022-2023 | Monjuvi |
| Kite Pharma, INC. | $61.70 | 2023 | Yescarta |
| Genentech USA, INC. | $58.58 | 2022-2023 | Phesgo |
| Dendreon Pharmaceuticals LLC | $54.18 | 2024-2025 | Provenge |
| Beone Medicines USA, INC. | $53.22 | 2025 | Tevimbra, Brukinsa |
| Celgene Corporation | $52.78 | 2022-2023 | Opdualag |
| Geron Corporation | $47.03 | 2025 | Rytelo |
| Genzyme Corporation | $44.90 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $43.63 | 2025 | |
| Mirati Therapeutics, INC. | $40.80 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $39.68 | 2022-2025 | |
| Exelixis INC. | $34.75 | 2025 | Cabometyx |
| Recordati_rare_diseases_inc. | $27.11 | 2025 | Enjaymo |
| Adaptive Biotechnologies Corporation | $24.25 | 2024 | Clonoseq |
| Sumitomo Pharma America, INC. | $24.14 | 2024 | Orgovyx |
| Eisai INC. | $24.09 | 2025 | |
| Epizyme, INC. | $24.08 | 2022 | |
| Foundation Medicine, INC. | $22.29 | 2023 | |
| Alexion Pharmaceuticals, INC. | $20.81 | 2024 | Ultomiris |
| Acrotech Biopharma INC. | $20.42 | 2023 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $19.40 | 2023 | Fotivda |
| Blueprint Medicines Corporation | $19.27 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.79 | 2025 | |
| Menarini Silicon Biosystems, INC. | $17.14 | 2024 | |
| Syndax Pharmaceuticals, INC. | $14.87 | 2025 | |
| Secura Bio, INC. | $14.79 | 2024 | Copiktra |
| Rigel Pharmaceuticals, INC. | $13.74 | 2021 | |
| Genmab U.S., INC. | $13.62 | 2024 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.